LL1_LASLA
ID LL1_LASLA Reviewed; 15 AA.
AC C0HK42;
DT 02-NOV-2016, integrated into UniProtKB/Swiss-Prot.
DT 02-NOV-2016, sequence version 1.
DT 02-JUN-2021, entry version 5.
DE RecName: Full=Lasioglossin-1 {ECO:0000303|PubMed:19591185};
DE Short=LL-I {ECO:0000303|PubMed:19591185};
OS Lasioglossum laticeps (Bee).
OC Eukaryota; Metazoa; Ecdysozoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Apoidea;
OC Halictidae; Halictinae; Halictini; Lasioglossum; Evylaeus.
OX NCBI_TaxID=88510 {ECO:0000303|PubMed:19591185};
RN [1] {ECO:0000305}
RP PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, MASS SPECTROMETRY,
RP IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE BY NMR, MUTAGENESIS OF
RP 1-VAL-ASN-2 AND GLY-8, AND AMIDATION AT LYS-15.
RC TISSUE=Venom {ECO:0000303|PubMed:19591185};
RX PubMed=19591185; DOI=10.1002/cbic.200900133;
RA Cerovsky V., Budesinsky M., Hovorka O., Cvacka J., Voburka Z.,
RA Slaninova J., Borovickova L., Fucik V., Bednarova L., Votruba I.,
RA Straka J.;
RT "Lasioglossins: three novel antimicrobial peptides from the venom of the
RT eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae).";
RL ChemBioChem 10:2089-2099(2009).
CC -!- FUNCTION: Antimicrobial peptide which assumes an amphiphilic alpha-
CC helix conformation upon contact with membranes (PubMed:19591185).
CC Insertion into membranes involves Trp-3 (By similarity). Penetrates
CC into cells once membrane has been permeated (By similarity). Active
CC against Gram-negative bacteria E.coli (MIC=1.7 uM), P.aeruginosa
CC (MIC=15.8 uM) and Gram-positive bacteria S.aureus (MIC=14.3 uM) and
CC B.subtilis (MIC=0.8 uM). Has cytotoxic but no hemolytic activity
CC (PubMed:19591185). Binds DNA in vitro (By similarity).
CC {ECO:0000250|UniProtKB:C0HK43, ECO:0000250|UniProtKB:C0HK44,
CC ECO:0000269|PubMed:19591185}.
CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19591185}.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC {ECO:0000305|PubMed:19591185}.
CC -!- PTM: The C-terminal amidation is required for full activity.
CC {ECO:0000250|UniProtKB:C0HK44}.
CC -!- MASS SPECTROMETRY: Mass=1722.1; Mass_error=0.1; Method=Electrospray;
CC Evidence={ECO:0000269|PubMed:19591185};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Antibiotic; Antimicrobial; Direct protein sequencing;
KW DNA-binding; Secreted.
FT PEPTIDE 1..15
FT /note="Lasioglossin-1"
FT /evidence="ECO:0000269|PubMed:19591185"
FT /id="PRO_0000437650"
FT MOD_RES 15
FT /note="Lysine amide"
FT /evidence="ECO:0000269|PubMed:19591185"
FT MUTAGEN 1..2
FT /note="VN->NV: Reduced antimicrobial activity."
FT /evidence="ECO:0000269|PubMed:19591185"
FT MUTAGEN 8
FT /note="G->A: Slightly increased activity against all
FT bacteria except P.aeruginosa."
FT /evidence="ECO:0000269|PubMed:19591185"
FT MUTAGEN 8
FT /note="G->K: Slightly increased activity against B.subtilis
FT and E.coli, reduced activity aginst S.aureus and
FT P.aeruginosa."
FT /evidence="ECO:0000269|PubMed:19591185"
FT MUTAGEN 8
FT /note="G->P: Reduced antimicrobial activity."
FT /evidence="ECO:0000269|PubMed:19591185"
SQ SEQUENCE 15 AA; 1724 MW; 2603143CD4C7E7B6 CRC64;
VNWKKVLGKI IKVAK